[Gold therapy and agranulocytosis].
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D000632:Aminopyrine / Q000009:adverse effects; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D001593:Benzyl Compounds / Q000009:adverse effects; D003094:Collagen / Q000494:pharmacology; D004123:Dimethylamines / Q000009:adverse effects; D004912:Erythrocytes; D005260:Female; D006046:Gold / Q000009:adverse effects* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007191:Indazoles / Q000009:adverse effects; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008875:Middle Aged; D010653:Phenylbutazone / Q000009:adverse effects; D011241:Prednisone / Q000627:therapeutic use; D012459:Salicylates / Q000627:therapeutic use; D013582:Synovial Fluid; D013885:Thiosulfates / Q000009:adverse effects / Q000627:therapeutic use; D014228:Triaziquone / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D001593:Benzyl Compounds; D004123:Dimethylamines; D007166:Immunosuppressive Agents; D007191:Indazoles; D012459:Salicylates; D013885:Thiosulfates; D000632:Aminopyrine; D006046:Gold; D003094:Collagen; D014228:Triaziquone; D010653:Phenylbutazone; D001241:Aspirin; D011241:Prednisone; D007213:Indomethacin
Goldtherapie und Agranulozytose.